2.3.2. Cytotoxicity

To analyze the application of compound **7**'s VEGFR-2 inhibitory potential against cancer*,* in vitro cytotoxicity studies were conducted using human breast cancer MCF-7, and colon cancer HCT 116 cell lines, with sorafenib as a reference. Table 5 and Figure 18 show that compound **7** could inhibit the growth of the MCF-7 and HCT 116 cell lines, exhibiting IC50 values of 12.93 and 11.52 μM, respectively, in comparison with sorafenib's anticancer potentialities against the same cell lines (4.32 and 7.28 μM, respectively).



**Figure 18.** VGFER-2 inhibition and cytotoxicity of compound **7** and sorafenib.

#### 2.3.3. Safety Evaluation

Against normal human cells, W138 cell lines, compound **7** was administered to test its toxicity and to determine its selectivity against cancer cell lines. Notably, compound **7** showed a very high level of safety, manifesting an IC50 of 87.26 μM. The obtained selectivity indexes (SI) of compound **7** against MCF-7 and HCT 116 cancer cell lines were very high, at 6.7 and 7.5, respectively.
